IRIS PubliCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.672
EU - Europa 7.389
AS - Asia 2.422
AF - Africa 45
SA - Sud America 30
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 17.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.602
DE - Germania 1.905
SE - Svezia 1.474
CN - Cina 991
IT - Italia 794
PL - Polonia 747
FR - Francia 734
SG - Singapore 707
UA - Ucraina 597
IE - Irlanda 436
ID - Indonesia 269
IN - India 228
FI - Finlandia 199
GB - Regno Unito 194
RU - Federazione Russa 135
TR - Turchia 70
CA - Canada 56
BE - Belgio 54
IR - Iran 45
HK - Hong Kong 29
NL - Olanda 28
JP - Giappone 25
CI - Costa d'Avorio 17
CH - Svizzera 15
BR - Brasile 13
ES - Italia 13
LT - Lituania 12
AT - Austria 10
AU - Australia 9
CM - Camerun 9
KZ - Kazakistan 9
EU - Europa 8
KR - Corea 8
MX - Messico 8
TW - Taiwan 8
VN - Vietnam 8
CL - Cile 7
RO - Romania 7
CZ - Repubblica Ceca 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
BG - Bulgaria 4
DK - Danimarca 4
NG - Nigeria 4
CO - Colombia 3
EG - Egitto 3
PA - Panama 3
PE - Perù 3
PK - Pakistan 3
PT - Portogallo 3
TH - Thailandia 3
AR - Argentina 2
BZ - Belize 2
EC - Ecuador 2
EE - Estonia 2
IM - Isola di Man 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
TZ - Tanzania 2
YE - Yemen 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KE - Kenya 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NZ - Nuova Zelanda 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
UZ - Uzbekistan 1
ZW - Zimbabwe 1
Totale 17.577
Salva come PNG Salva come JPEG
Città #
Chandler 1.886
Ashburn 662
Kraków 599
Singapore 545
Dublin 429
Jacksonville 416
San Mateo 381
New York 375
Jakarta 268
Milan 240
Nanjing 227
Wilmington 214
Ann Arbor 178
Boston 175
Dearborn 164
Houston 152
Warsaw 145
Cattolica 126
Princeton 123
Lawrence 122
Nürnberg 110
Woodbridge 105
Redwood City 103
Beijing 102
Moscow 97
Nanchang 95
Rome 78
Marseille 75
Redmond 74
Seattle 73
Izmir 65
Helsinki 61
Los Angeles 59
Fairfield 57
Lancaster 56
Boardman 55
Brussels 54
Shenyang 52
Bremen 51
Mountain View 49
Norwalk 45
Chicago 43
Changsha 42
Munich 42
Kunming 41
Pune 40
Hebei 37
University Park 37
Augusta 32
Verona 31
Ottawa 29
Leawood 27
Tianjin 27
Shanghai 26
Fremont 25
Cambridge 24
Guangzhou 24
Hangzhou 24
Jiaxing 24
Andover 22
Jinan 22
Toronto 22
Hong Kong 21
London 21
Washington 21
Kish 19
Hefei 18
Philadelphia 18
Abidjan 17
Amsterdam 17
Falls Church 16
Santa Clara 15
Edinburgh 13
Frankfurt am Main 13
Paris 13
Zhengzhou 13
San Jose 12
Busto Arsizio 11
Changchun 11
Simi Valley 11
Detroit 9
Fuzhou 9
Turin 9
Sacramento 8
San Francisco 8
Springfield 8
Tavagnacco 8
Vienna 8
Atlanta 7
Indiana 7
Phoenix 7
Almaty 6
Berlin 6
Chengdu 6
Las Vegas 6
Tappahannock 6
Auburn Hills 5
Baltimore 5
Clearwater 5
Costa Mesa 5
Totale 10.002
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 320
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 210
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 176
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 175
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 170
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 165
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 160
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 151
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 151
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 140
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 139
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 139
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 136
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 134
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 133
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 132
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 129
Variability of raltegravir plasma levels in the clinical setting 125
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 123
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 122
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 120
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 120
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 115
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 109
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 109
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 108
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 108
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 108
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 108
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 106
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 106
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 105
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 105
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 105
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 103
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 102
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 102
Cognitive reserve and neuropsychological functioning in older HIV-infected people 101
Effect of aging and human immunodeficiency virus infection on cognitive abilities 100
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 100
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 100
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 100
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 98
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 98
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 98
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 97
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 97
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 96
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 96
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 95
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 95
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 94
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 93
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 92
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 92
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 92
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 92
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 91
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 91
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 91
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 90
Mortality in patients with early- or late-onset candidaemia 90
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 89
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 88
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 87
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 86
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 86
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 86
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 85
Mortality in patients, with early-or late-onset candidaemia 85
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 85
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 84
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 83
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 82
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 82
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 82
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 82
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 82
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 80
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 80
Long term follow-up of Nevirapine-treated patients in a single centre cohort 79
Lipid-lowering effect of tenofovir in HIV-infected patients 79
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 79
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 79
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 78
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 77
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 77
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 76
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 76
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 76
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 76
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 76
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort 74
Interpretation systems for genotypic drug resistance of HIV-1 73
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 73
Shall we dance? Extending tango's results to clinical practice 73
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 73
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 72
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 72
Totale 10.406
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.488
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.488
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.132 0 0 0 0 125 187 107 70 132 111 244 156
2020/20211.423 112 155 33 142 165 85 134 24 210 77 246 40
2021/20222.108 174 125 40 173 76 63 96 376 79 151 298 457
2022/20234.750 650 729 362 682 373 586 139 393 584 48 146 58
2023/20242.505 94 661 51 311 96 502 116 46 57 68 281 222
2024/20251.221 77 107 457 151 429 0 0 0 0 0 0 0
Totale 17.899